公开(公告)号：US20170252352A1

公开(公告)日：2017-09-07

申请号：US15314574

申请日：2015-05-18

Applicant: Pfizer Inc.

Inventor： Eugene Lvovich Piatnitski CHEKLER ,  Adam Matthew GILBERT ,  Rayomand Jal UNWALLA ,  Patrick Robert VERHOEST ,  James Thomas ANDERSON

IPC: A61K31/549 ,  A61K31/433 ,  A61K31/472 ,  A61K45/06 ,  A61K31/397 ,  A61K31/451 ,  A61K31/402 ,  A61K31/4725 ,  A61K31/277

CPC classification number: A61K31/549 ,  A61K31/277 ,  A61K31/397 ,  A61K31/402 ,  A61K31/433 ,  A61K31/451 ,  A61K31/472 ,  A61K31/4725 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH2)q—, —(CHRs)q—, or —(CRsRt)q—, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.